Today's pre-market stock movers: CHWY, PATH, SNAP, HPE and more
Gainers:
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $NetApp(NTAP.US$+3.4% (In reaction to earnings)
• $Comtech Telecommunications(CMTL.US$ +2.7% (receives 5G contract with mobile network operator in Saudi Arabia)
• $ANI Pharmaceuticals(ANIP.US$ +2.5% (receives FDA approval for ANDA for Fludrocortisone Acetate Tablets)
• $DHI Group(DHX.US$+1.4% (US PTO issues patent related to taxonomy)
• $Silk Road Medical(SILK.US$ +1.3% (CMS has expanded coverage for TCAR to include standard surgical risk patients within the VQI's TCAR
• $Cedar Fair(FUN.US$+1.1% (YTD update)
• $Boyd Gaming(BYD.US$+1.1% (authorizes $500 mln increase to share repurchase program)
• $Semtech(SMTC.US$+1% (In reaction to earnings)
• $GameStop(GME.US$+0.8% (In reaction to earnings)
Analyst comments:
• $Ecolab(ECL.US$+1.6% (upgraded to Buy from Neutral at UBS)
• $Dentsply Sirona(XRAY.US$+1.1% (upgraded to Buy from Neutral at UBS)
Losers:
• $Immunic(IMUX.US$ -62.2% (reported top-line data from its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium)
• $Immunic(IMUX.US$ -62.2% (reported top-line data from its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium)
• $C3.ai(AI.US$-19.4%(In reaction to earnings)
• $Centessa Pharmaceuticals(CNTA.US$-8.9% (to discontinue clinical development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease)
• $Hewlett Packard Enterprise(HPE.US$-5.5% (earnings and sales miss amid 'inflationary environment and ongoing supply-chain disruptions')
• $Concert Pharmaceuticals(CNCE.US$ -5% (prices offering of 10 mln shares of common stock at $4.75 per share)
•$Magnolia Oil & Gas(MGY.US$ -4.7% (announces proposed block trade of 7.5 mln Class A shares by selling shareholders; intends to purchase 2 mln Class B shares)
• $Blue Owl Capital(OWL.US$ -3.1% (prices secondary offering by NBSH Blue Investments II of 10,698,180 shares of Class A common stock at $11.50 per share)
• $American Tower Corp(AMT.US$-2.9% (intends to offer 8,350,000 shares of its common stock in a registered public offering)
• $Ciena(CIEN.US$-2.8% (In reaction to earnings)
• $International Game Technology(IGT.US$-1.7% (signs ten year contract extension with Kansas lottery)
• $Moderna(MRNA.US$ -1.4% (Moderna and EC to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate)
• $Enochian Biosciences(ENOB.US$ -1.2% (published on its website a letter to shareholders to clarify "several misrepresentations")
• $Radius Health(RDUS.US$ -1.1% (provides update on abaloparatide transdermal system; to cease all work on abalo-TDS)
Analyst comments:
• $Albemarle(ALB.US$-2.3% (downgraded to Neutral from Buy at UBS)
• $Crown Castle(CCI.US$-1.6% (downgraded to Underweight from Equal Weight at Wells Fargo)
Moomoo is an app offered by Moomoo Technologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.
Comment
Sign in to post a comment